BCAL: The Early Detection Company Anne-Louise Arnett Chief Executive Officer (ASX: BDX) 6 th August 2026 T14 | Session 3: Diagnostics Feature BCAL Diagnostics | 20th Bioshares Biotech Summit 2026 Who is BCAL BCAL Diagnostics | 20th Bioshares Biotech Summit 2026 3 Experienced...
Bioshares Conference Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
BCAL Diagnostics Limited on 6ix
In the deck
Story so far
Earlier from BCAL Diagnostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- BCAL to Acquire Shares in Genetic Signatures
- BCAL Secures Funding for FY2027
- BCAL Develops New Blood Test for Breast Cancer Recurrence
- BCAL Launches Early Detection Cancer Platform
Later from BCAL Diagnostics
- Proposed issue of securities - BDX
- Notification regarding unquoted securities - BDX
- BCAL Secures Funding for FY2027 Update
- Change in Substantial Shareholder Notice for GSS
- BCAL Takes Interest in Genetic Signatures to 18.46%
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics